Zhang Lisong, Fisher Elizabeth, Bradbury Naomi, Darko Natalie, Khunti Kamlesh, Lock Selina, Singh Sally J, Simpson Sharon A, Smith Ellesha, Smith Susan M, Taylor Rod S, Witham Miles, Young Hannah, Gray Laura J
Department of Population Health Sciences, University of Leicester, Leicester, United Kingdom.
NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom.
PLoS One. 2025 Jun 30;20(6):e0325742. doi: 10.1371/journal.pone.0325742. eCollection 2025.
The number of people living with multiple long-term conditions (MLTC or multimorbidity) is increasing. There have been national and international calls for more and better research in this clinical area. This systematic review will assess the methodological approaches, risk of bias and standards of reporting of the included trials. This study will benchmark current methodological practice and identify areas for improvement.
MEDLINE, Scopus, CINAHL, CENTRAL and the International Research Community in Multimorbidity database will be searched from January 1999 to identify randomised controlled trials conducted with the aim of improving health outcomes for people living with MLTCs. Study screening, data extraction and the risk of bias assessment will be conducted independently by two reviewers. Data to be extracted will include study descriptors, design and analysis characteristics, methodological quality, bias and standard of reporting. A narrative synthesis will be conducted to summarise current methodological practice and to identify areas for improvement.
Ethical approval is not required. The results of the review will be published in a peer-reviewed journal and shared via conferences and webinars. PROSPERO registration number: CRD42024595925.
患有多种长期疾病(MLTC或共病)的人数正在增加。国内外都呼吁在这一临床领域开展更多更好的研究。本系统评价将评估纳入试验的方法学方法、偏倚风险和报告标准。本研究将对当前的方法学实践进行基准评估,并确定改进领域。
将检索1999年1月以来的MEDLINE、Scopus、CINAHL、CENTRAL和国际共病研究社区数据库,以识别旨在改善患有多种长期疾病患者健康结局的随机对照试验。由两名 reviewers 独立进行研究筛选、数据提取和偏倚风险评估。要提取的数据将包括研究描述符、设计和分析特征、方法学质量、偏倚和报告标准。将进行叙述性综合,以总结当前的方法学实践并确定改进领域。
无需伦理批准。评价结果将发表在同行评审期刊上,并通过会议和网络研讨会分享。PROSPERO注册号:CRD42024595925。